Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Other Accumulated Expenses (2020 - 2025)

Beam Therapeutics (BEAM) has disclosed Other Accumulated Expenses for 6 consecutive years, with $2.0 million as the latest value for Q4 2025.

  • Quarterly Other Accumulated Expenses fell 74.59% to $2.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.0 million through Dec 2025, down 74.59% year-over-year, with the annual reading at $2.0 million for FY2025, 74.59% down from the prior year.
  • Other Accumulated Expenses for Q4 2025 was $2.0 million at Beam Therapeutics, down from $2.7 million in the prior quarter.
  • The five-year high for Other Accumulated Expenses was $28.6 million in Q4 2023, with the low at $2.0 million in Q4 2025.
  • Average Other Accumulated Expenses over 5 years is $9.5 million, with a median of $7.0 million recorded in 2021.
  • The sharpest move saw Other Accumulated Expenses skyrocketed 212.95% in 2024, then plummeted 90.49% in 2025.
  • Over 5 years, Other Accumulated Expenses stood at $7.0 million in 2021, then surged by 76.08% to $12.3 million in 2022, then surged by 133.58% to $28.6 million in 2023, then tumbled by 72.73% to $7.8 million in 2024, then crashed by 74.59% to $2.0 million in 2025.
  • According to Business Quant data, Other Accumulated Expenses over the past three periods came in at $2.0 million, $2.7 million, and $2.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.